| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
|
Davids, Matthew S
|
|
|
22 |
10 |
p. 1391-1402
|
artikel
|
| 2 |
Access to and affordability of cancer medicines: time to focus on the last mile
|
Sirohi, Bhawna
|
|
|
22 |
10 |
p. 1342-1343
|
artikel
|
| 3 |
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
|
Fundytus, Adam
|
|
|
22 |
10 |
p. 1367-1377
|
artikel
|
| 4 |
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
|
Valle, Juan W
|
|
|
22 |
10 |
p. 1468-1482
|
artikel
|
| 5 |
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial
|
Hackshaw, Allan
|
|
|
22 |
10 |
p. 1360-1362
|
artikel
|
| 6 |
Anticipating the COVID-19-related surge in cancer care demand is urgent in Latin America and the Caribbean
|
Herrera, Cristian A
|
|
|
22 |
10 |
p. 1350-1352
|
artikel
|
| 7 |
Artificial intelligence and cancer diagnosis: caution needed
|
Venkatesan, Priya
|
|
|
22 |
10 |
p. 1364
|
artikel
|
| 8 |
Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment
|
Lengliné, Etienne
|
|
|
22 |
10 |
p. e430-e434
|
artikel
|
| 9 |
Bilateral lower extremity induration in a patient with leiomyosarcoma
|
Lee, Michelle S
|
|
|
22 |
10 |
p. e466
|
artikel
|
| 10 |
CAR T cells for the long run in aggressive B-cell lymphoma
|
Jacoby, Elad
|
|
|
22 |
10 |
p. 1347-1348
|
artikel
|
| 11 |
Childhood cancer control during the COVID-19 pandemic
|
Luna-Fineman, Sandra
|
|
|
22 |
10 |
p. 1348-1350
|
artikel
|
| 12 |
Climate crisis and cancer: the need for urgent action
|
The Lancet Oncology,
|
|
|
22 |
10 |
p. 1341
|
artikel
|
| 13 |
Correction to Lancet Oncol 2021; 22: 1301–11
|
|
|
|
22 |
10 |
p. e428
|
artikel
|
| 14 |
Correction to Lancet Oncol 2020; 21: 1465–77
|
|
|
|
22 |
10 |
p. e428
|
artikel
|
| 15 |
Correction to Lancet Oncol 2020; 21: 271–82
|
|
|
|
22 |
10 |
p. e428
|
artikel
|
| 16 |
Daratumumab for post-ASCT maintenance treatment of myeloma
|
Kapoor, Prashant
|
|
|
22 |
10 |
p. 1345-1347
|
artikel
|
| 17 |
Developments in lung cancer biology in never-smokers
|
Burki, Talha Khan
|
|
|
22 |
10 |
p. 1363
|
artikel
|
| 18 |
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis
|
Ward, Zachary J
|
|
|
22 |
10 |
p. 1427-1437
|
artikel
|
| 19 |
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
|
Del Mastro, Lucia
|
|
|
22 |
10 |
p. 1458-1467
|
artikel
|
| 20 |
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Pinto, Carmine
|
|
|
22 |
10 |
p. 1438-1447
|
artikel
|
| 21 |
Gestational trophoblastic neoplasia: one size does not fit all
|
Paulino, Eduardo
|
|
|
22 |
10 |
p. e420
|
artikel
|
| 22 |
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply
|
Braga, Antonio
|
|
|
22 |
10 |
p. e421
|
artikel
|
| 23 |
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
|
Mukkada, Sheena
|
|
|
22 |
10 |
p. 1416-1426
|
artikel
|
| 24 |
Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension
|
Kendall, Timothy J
|
|
|
22 |
10 |
p. e435-e445
|
artikel
|
| 25 |
HER2-low-positive breast cancer from four neoadjuvant clinical trials
|
Omar, Abeid
|
|
|
22 |
10 |
p. e426
|
artikel
|
| 26 |
HER2-low-positive breast cancer from four neoadjuvant clinical trials – Authors' reply
|
Denkert, Carsten
|
|
|
22 |
10 |
p. e427
|
artikel
|
| 27 |
Importance of modelling for cancer management during COVID-19
|
Paris, Enrique
|
|
|
22 |
10 |
p. 1352-1353
|
artikel
|
| 28 |
Inappropriate censoring in Kaplan-Meier analyses
|
Fojo, Tito
|
|
|
22 |
10 |
p. 1358-1360
|
artikel
|
| 29 |
Late phase 1 studies: concepts and outcomes
|
Benitez, Jose Carlos
|
|
|
22 |
10 |
p. e446-e455
|
artikel
|
| 30 |
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
|
Rahman, Rifaquat
|
|
|
22 |
10 |
p. e456-e465
|
artikel
|
| 31 |
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
|
Schuster, Stephen J
|
|
|
22 |
10 |
p. 1403-1415
|
artikel
|
| 32 |
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
|
Moreau, Philippe
|
|
|
22 |
10 |
p. 1378-1390
|
artikel
|
| 33 |
Optimal adjuvant endocrine therapy for breast cancer
|
Yung, Rachel L
|
|
|
22 |
10 |
p. 1357-1358
|
artikel
|
| 34 |
Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?
|
Mano, Max S
|
|
|
22 |
10 |
p. 1365-1366
|
artikel
|
| 35 |
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer
|
Hindié, Elif
|
|
|
22 |
10 |
p. e425
|
artikel
|
| 36 |
Shortages of essential medications for children with cancer in Colombia
|
Bustamante, Luz Urcuqui
|
|
|
22 |
10 |
p. 1343-1345
|
artikel
|
| 37 |
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery
|
Chang, Joe Y
|
|
|
22 |
10 |
p. 1448-1457
|
artikel
|
| 38 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer
|
Okano, Naohiro
|
|
|
22 |
10 |
p. e423
|
artikel
|
| 39 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer – Authors' reply
|
Zhu, Xiaofei
|
|
|
22 |
10 |
p. e424
|
artikel
|
| 40 |
Surgery versus SABR for early-stage lung cancer—time to call it a draw?
|
Louie, Alexander V
|
|
|
22 |
10 |
p. 1355-1357
|
artikel
|
| 41 |
The CReDO workshop: a promising venture needing urgent reform
|
Sarode, Gargi S
|
|
|
22 |
10 |
p. e422
|
artikel
|
| 42 |
Understanding the new therapeutic options for mesothelioma
|
Kindler, Hedy Lee
|
|
|
22 |
10 |
p. 1353-1355
|
artikel
|
| 43 |
2021 World Conference on Lung Cancer
|
Landman, Allison
|
|
|
22 |
10 |
p. e429
|
artikel
|
Tijdschrift beschrijving